Download PDF
Exp Clin Endocrinol Diabetes 2007; 115(5): 322-326
DOI: 10.1055/s-2007-960493
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

TNF-alpha -308G>A Polymorphism Modulates Cytokine Serum Concentrations and Macrovascular Complications in Diabetic Patients on Aspirin

P.-A. Krayenbuehl 1 , P. Wiesli 1 , M. Schmid 2 , C. Schmid 2 , J. A. Ehses 2 , M. Hersberger 3 , W. Vetter 1 , G. Schulthess 1
  • 1Department of Internal Medicine, Medical Policlinic, University Hospital of Zurich, Zurich, Switzerland
  • 2Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital of Zurich, Zurich, Switzerland
  • 3Institute of Clinical Chemistry, University Hospital of Zurich, Zurich, Switzerland
Further Information

Publication History

received 28. 8. 2006 first decision 5. 10. 2006

accepted 24. 11. 2006

Publication Date:
21 May 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Tumor necrosis factor (TNF)-α has pleiotropic effects in cytokine-mediated inflammation underlying atherogenesis. Activation of this inflammatory process is assumed to be different in diabetic and non-diabetic individuals. Previous studies in non-diabetic subjects showed no association between TNF-α -308G>A polymorphism and coronary artery disease.

Methods: Vascular complications and cytokine serum concentrations were assessed as a function of the TNF-α -308G>A polymorphism in 76 diabetic patients on low-dose aspirin.

Results: Of 76 adult diabetic patients, 18 (24%) carried the TNF-α -308A allele (17 AG, 1 AA) and 58 (76%) carried wild-type alleles (GG). Prevalence of macrovascular complications was 33% in TNF-α -308A allele carriers (AG+AA) and 78% in wild-type allele carriers (GG) (p<0.001). In contrast, prevalence of microvascular complications was 78% and 84%, respectively, and did not significantly differ between the study groups. TNF-α -308A allele carriers (AG+AA) compared to wild-type allele carriers (GG) had significantly lower median serum concentrations of hs-C-reactive protein (1.5 vs 2.9 mg/L, p=0.030), interleukin 1-β (0.9 vs 1.2 ng/L, p=0.046), and interleukin-6 (3.6 vs 4.9 ng/L, p=0.023). In multiple regression analysis, the prevalence of macrovascular diabetic complications was significantly associated with TNF-α -308G>A polymorphism (p<0.001) and serum concentrations of HDL-cholesterol (p=0.007) while confounding effects of further variables were excluded.

Conclusion: TNF-α -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Diabetic carriers of the TNF-α -308A allele might benefit more from a prophylaxis with low dose aspirin than non-carriers.

Key words

Diabetes mellitus - TNF-alpha - aspirin - cardiovascular events - hs-C-reactive protein - hs-CRP

References

  • 1 Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease.  J Leukoc Biol. 1999;  66 562-566
    PubMedGoogle Scholar
  • 2 Albertini JP, Valensi P, Lormeau B, Aurousseau MH, Ferriere F, Attali JR, Gattegno L. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes.  Care. 1998;  21 1008-1013
    PubMedGoogle Scholar
  • 3 Altarescu G, Zimran A, Michelakakis H, Elstein D. levels and TNF-alpha gene polymorphism in type I Gaucher disease.  Cytokine. 2005;  31 149-152
    CrossrefPubMedGoogle Scholar
  • 4 Antithrombotic Trialists’ Collaboration: . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
    CrossrefPubMedGoogle Scholar
  • 5 Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forester JS. Detection and localization of tumor necrosis factor in human atheroma.  Am J Cardiol. 1990;  65 297-302
    CrossrefPubMedGoogle Scholar
  • 6 Ceriello A, Motz E. Prevention of vascular events in diabetes mellitus: which “antithrombotic” therapy?.  Diabetologia. 1996;  39 1405-1406
    CrossrefPubMedGoogle Scholar
  • 7 Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes.  Diabetes. 2005;  54 97-107
    CrossrefPubMedGoogle Scholar
  • 8 Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events.  Diabetes Care. 2003;  26 2181-2188
    CrossrefPubMedGoogle Scholar
  • 9 Colwell JA. Aspirin therapy in diabetes.  Diabetes Care. 2004;  27 ((Suppl 1)) S72-73
    CrossrefPubMedGoogle Scholar
  • 10 Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease.  Circulation. 1999;  99 861-866
    PubMedGoogle Scholar
  • 11 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation.  N Engl J Med. 1999;  340 448-454
    CrossrefPubMedGoogle Scholar
  • 12 Gao J, Shan G, Sun B, Thompson PJ, Gao X. Association between polymorphism of tumour necrosis factor {alpha}-308 gene promoter and asthma: a meta-analysis.  Thorax. 2006;  61 466-471
    CrossrefPubMedGoogle Scholar
  • 13 Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saro C, Dieguez MA, Lopez-Larrea C. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease.  Am J Gastroenterol. 2003;  98 1101-1106
    PubMedGoogle Scholar
  • 14 Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, Duff GW, Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region.  J Hepatol. 1999;  31 242-247
    CrossrefPubMedGoogle Scholar
  • 15 Haffner SM. Coronary heart disease in patients with diabetes.  N Engl J Med. 2000;  342 1040-1042
    CrossrefPubMedGoogle Scholar
  • 16 Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease.  Hum Immunol. 2001;  62 1191-1199
    CrossrefPubMedGoogle Scholar
  • 17 Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications.  Cardiol Rev. 2006;  14 18-25
    CrossrefPubMedGoogle Scholar
  • 18 Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis.  Arteriosclerosis. 1989;  9 567-578
    PubMedGoogle Scholar
  • 19 Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, Ruidavets JB, Luc G, Bara L, Parra HJ, Poirier O, Cambien F. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity.  Eur J Clin Invest. 1998;  28 59-66
    CrossrefPubMedGoogle Scholar
  • 20 Jones DE, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL, Day CP, James OF, Bassendine MF. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis.  J Hepatol. 1999;  30 232-236
    CrossrefPubMedGoogle Scholar
  • 21 Kaartinen M, Penttilä A, Kovanen PT. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-α.  Circulation. 1996;  94 2787-2792
    PubMedGoogle Scholar
  • 22 Kallas EG, Reynolds K, Andrews J, Treanor JJ, Evans TG. Production of influenza-stimulated tumor necrosis factor-alpha by monocytes following acute influenza infection in humans.  J Interferon Cytokine Res. 1999;  19 751-755
    CrossrefPubMedGoogle Scholar
  • 23 Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading.  Nat Genet. 2003;  33 469-475
    PubMedGoogle Scholar
  • 24 Knopp RH, Retzlaff B, Aikawa K, Kahn SE. Management of patients with diabetic hyperlipidemia.  Am J Cardiol. 2003;  91 ((7A)) 24E-28E
    CrossrefPubMedGoogle Scholar
  • 25 Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction.  Atherosclerosis. 2001;  159 137-144
    CrossrefPubMedGoogle Scholar
  • 26 Krayenbuehl P, Maly FE, Hersberger M, Wiesli P, Himmelmann A, Eid K, Greminger P, Vetter W, Schulthess G. Tumor Necrosis Factor-α -308G>A polymorphism modulates iron accumulation in patients with hereditary hemochromatosis.  Clin Chem. 2006;  52 1552-1558
    CrossrefPubMedGoogle Scholar
  • 27 Krikovszky D, Vasarhelyi B, Toth-Heyn P, Korner A, Tulassay T, Madacsy L. Association between -308G>A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents.  Clin Genet. 2002;  62 474-477
    CrossrefPubMedGoogle Scholar
  • 28 Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?.  Diabetes. 2005;  54 ((Suppl 2)) S114-124
    CrossrefPubMedGoogle Scholar
  • 29 Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription.  Mol Immunol. 1997;  34 391-399
    CrossrefPubMedGoogle Scholar
  • 30 Kutuk O, Basaga H. Aspirin inhibits TNFalpha- and IL-1-induced NF-kappaB activation and sensitizes HeLa cells to apoptosis.  Cytokine. 2004;  25 229-237
    CrossrefPubMedGoogle Scholar
  • 31 Libby P. Molecular bases of the acute coronary syndromes.  Circulation. 1995;  91 2844-2850
    CrossrefPubMedGoogle Scholar
  • 32 Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B, Heesen M. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients.  Clin Diagn Lab Immunol. 2002;  9 1205-1211
    CrossrefPubMedGoogle Scholar
  • 33 Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein.  Diabetes Care. 2005;  28 690-693
    PubMedGoogle Scholar
  • 34 McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.  Nature. 1994;  371 508-510
    CrossrefPubMedGoogle Scholar
  • 35 Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study.  JAMA. 1999;  282 561-568
    CrossrefPubMedGoogle Scholar
  • 36 Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients.  Diabetes. 1997;  46 2096-2101
    CrossrefPubMedGoogle Scholar
  • 37 Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women.  N Engl J Med. 2004;  351 2599-2610
    CrossrefPubMedGoogle Scholar
  • 38 Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes.  Am J Cardiol. 2001;  88 ((suppl)) 10K-15K
    PubMedGoogle Scholar
  • 39 Roberts WL. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation-performance and standardization: a background paper.  Circulation. 2004;  110 e572-576
    CrossrefPubMedGoogle Scholar
  • 40 Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G. Nicolucci A; PPP Collaborative Group . Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.  Diabetes Care. 2003;  26 3264-3272
    CrossrefPubMedGoogle Scholar
  • 41 Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism.  Am J Respir Crit Care Med. 2003;  168 476-480
    CrossrefPubMedGoogle Scholar
  • 42 Schiekofer S, Franke S, Andrassy M, Chen J, Rudofsky G, Schneider JG, von Eynatten M, Wendt T, Morcos M, Kientsch-Engel R, Stein G, Schleicher E, Nawroth PP, Bierhaus A. Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal.  Exp Clin Endocrinol Diabetes. 2006;  114 160-167
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes.  Diabetes Care. 2004;  27 889-894
    CrossrefPubMedGoogle Scholar
  • 44 Shin HD, Park BL, Kim LH, Jung JH, Wang HJ, Kim YJ. et al . Association of tumor necrosis factor polymorphisms with asthma and serum total IgE.  Hum Mol Genet. 2004;  13 397-403
    PubMedGoogle Scholar
  • 45 Sookoian S, Garcia SI, Gianotti TF, Dieuzeide G, Gonzalez CD, Pirola CJ. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome.  Am J Hypertens. 2005;  18 1271-1275
    CrossrefPubMedGoogle Scholar
  • 46 Staiger H, Häring HU. Adipocytokines: Fat-derived humoral mediators of metabolic homeostasis.  Exp Clin Endocrinol Diabetes. 2005;  113 67-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Tsiavou A, Hatziagelaki E, Chaidaroglou A, Manginas A, Koniavitou K, Degiannis D, Raptis A. TNF-α, TGF-β, IL-6, gene polymorphisms in latent autoimmune diabetes of adults and type 2 diabetes mellitus.  J Clin Immunol. 2004;  24 591-599
    CrossrefPubMedGoogle Scholar
  • 48 Vatay A, Rajczy K, Pozsonyi E, Hosszufalusi N, Prohaska Z, Füst G, Karadi I, Szalai C, Grosz A, Bartfai Z, Panczel P. Differences in the genetic backgroud of latent autoimmune diabetes in adults and type 1 diabetes mellitus.  Immunol Lett. 2002;  84 109-115
    CrossrefPubMedGoogle Scholar
  • 49 Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, Ricart W, Richart C. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients.  Atherosclerosis. 2003;  167 257-264
    CrossrefPubMedGoogle Scholar
  • 50 Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.  Proc Natl Acad Sci USA. 1997;  94 3195-3199
    CrossrefPubMedGoogle Scholar
  • 51 Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes.  N Engl J Med. 2002;  347 1916-1923
    CrossrefPubMedGoogle Scholar
  • 52 Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)-beta.  Nature. 1988;  396 77-80
    PubMedGoogle Scholar
  • 53 Zeggini E, Groves CJ, Parkinson JR, Halford S, Oven KR, Frayling TM. et al . Large-scale studies of the association between variations at the TNF/LTA locus and susceptibility to type 2 diabetes.  Diabetologica. 2005;  48 2013-2017
    CrossrefPubMedGoogle Scholar
  • 54 Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P. Association of TNF-alpha polymorphisms in Crohn disease.  Hum Immunol. 2005;  66 56-59
    PubMedGoogle Scholar

Correspondence

G. Schulthess

Medical Policlinic

University Hospital 8091

Zurich

Switzerland

Phone: +41/44/255 11 11

Fax: +41/44/255 45 67

Email: georg.schulthess@usz.ch

      >